S.R. Burzynski, MD, PhD invented antineoplastons, an experimental cancer therapy. Antineoplastons are made up of of peptides and amino acids found in blood and urine of humans. Antineoplastons were first extracted from human blood, and then the same peptides were discovered in urine. Urine was eventually used since it was less expensive and more readily available. The Burzynski Research Institute has been synthesising antineoplastons from widely accessible compounds since 1980.


Dr. Burzynski was certain that antineoplastons act as body’s natural defense system which can protect against cancer. Cancer patients usually lack these compounds. And thus this treatment may be effective. Antineoplastons, according to the inventor, are part of the body’s biochemical monitoring system and act as “molecular switches.” Cell differentiation is the key to cancer therapy. Abnormal cells that have the potential to become cancerous must be “switched” to normal mode at the molecular level.

Antineoplastons perform the surveillance mechanism that drives cancer cells into normal differentiation channels antineoplastons. People with cancer, do not have this lack this surveillance mechanism because the lack adequate antineoplastons. Dr. Burzynski describes antineoplastons as substances created by the living body that protect the body against the formation of neoplastic cells, through a non-immunological method that does not affect the growth of normal cells and tissues.

Antineoplastons are either given orally or by injections.

For cancer treatment, there have no phase III trials or randomized studies about antineoplastons. The effect of antineoplastons on cancer patients have been studied at the Burzynski clinic where antineoplastons were initially invented. Phase I clinical studies, phase II clinical trials, and case reports have been documented. Outside of the clinic, a few trials and case studies have been conducted. Breast, bladder, cervical, prostate, liver, lung, brain, leukaemia, and lymphoma were among the cancers studied. In the research, several patients received both standard therapy and antineoplastons. It’s unclear whether antineoplaston therapy or the other treatments produced the responses and side effects in those cases.

The US Food and Drug Administration (FDA) has not approved antineoplastons for the prevention or treatment of any disease.The FDA granted the innovator authorization to conduct antineoplaston treatment clinical studies at his own clinic. Antineoplaston therapy is only available in clinical trials at the developer’s facility in the United States.

Side effects

These drugs have mild to moderate side effects such as :

  • Anemia
  • High calcium levels in blood
  • Hypertension
  • Irregular heart rate
  • Headaches
  • Dizziness
  • Fever and chills
  • Nausea and vomiting
  • Anorexia
  • Gas and bloating
  • Dry or itchy skin
  • Numbness
  • Fatigue and insomnia
  • Edema in the tissues due to excess fluid
  • Joint pain and swelling
  • Brain fog
  • Seizures
  • Swelling near the brain

Drowsiness, brain fog, mental confusion, fits, and edema near the brain were some of the severe side effects that were noticed in a phase II trial in brain tumor patients.